About Us

Innovation for Good Health

WE'RE A FAST GROWING U.S. SUBSIDIARY OF A GLOBAL PHARMACEUTICAL GROUP

It's important to care for others and contribute to society

ABOUT US

Fosun Pharma USA Inc.

Fosun Pharma USA Inc., based in Princeton NJ, is led by a team of highly experienced executives with strong track records from leading US and European pharmaceutical companies both in commercial operations and R&D. Fosun Pharma USA today markets a portfolio of specialty pharmaceutical injectable products and ophthalmics and has a pipeline of innovative products. With its core commercial team in place, Fosun Pharma USA is building its commercial presence in the US market. We are now looking for late development stage (phase 2 and beyond) or commercial stage innovative products to in-license/partner with or acquire for the USA market. While we can facilitate a partnership with our parent company for the Chinese market, our clear focus is on US rights for innovative biopharmaceuticals.

STRATEGIC PARTNERSHIPS

Strategic alliances and partnerships form a critical foundation for our continued growth and success

Fosun Pharma USA’s areas of interest cover several therapeutic areas. An area of current focus is oncology. We have a pipeline of innovative oncology products in development and significant expertise in the field. We are actively looking for late development stage or commercial stage partnerships in oncology. We are agnostic to tumor type or technology platform. In other therapeutic areas, we are especially interested in near-to-market product opportunities.

For questions and additional information, please email [email protected]

Fosun Pharma Innovation Hub (FUSION BioVenture) is an incubation, innovation, and strategic investment platform of Fosun Pharma. FUSION invests in and incubates new startups developing cutting-edge technologies across therapeutic areas. By partnering with FUSION, in addition to early-stage financing, entrepreneurs are provided with access to the worldwide capabilities of Fosun Pharma across the life sciences value chain as well as shared access to core operational services.